J KEVIN BUCHI
CIK 1209726 · Chief Executive Officer · last filed 2026-05-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.56M
Companies
13
Total Filings
88
Lifetime Open-Market Net
-$4.63M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AMRX | Director | 337,149 | $18.76 | $6.32M | $0 | 11 | 2026-05-08 |
| BNTC | Director | 103,910 | $11.89 | $1.24M | $0 | 9 | 2025-12-03 |
| Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Director | 7,343 | $0.18 | $1.3K | $39.0K | 6 | 2023-06-13 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 0 | $38.22 | $0 | $0 | 6 | 2021-12-29 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 4,167 | $0.87 | $3.6K | $0 | 2 | 2021-05-06 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | Chief Executive Officer | — | — | — | $0 | 1 | 2019-10-25 |
| Impax Laboratories, LLC (IPXL) Delisted | Director | 11,301 | — | — | $0 | 2 | 2017-05-17 |
| STEMLINE THERAPEUTICS INC (STML) Delisted | Director | 23,772 | — | — | $5.0K | 3 | 2015-06-25 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | Director | — | — | — | $0 | 1 | 2015-06-25 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | Director | — | — | — | $0 | 2 | 2015-06-08 |
| TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | President & CEO | 330,714 | — | — | $2.21M | 8 | 2015-03-30 |
| CEPHALON INC (CEPH) Delisted | Chief Executive Officer | 0 | — | — | -$6.89M | 28 | 2011-10-17 |
| ENCYSIVE PHARMACEUTICALS INC (ENCY) Delisted | Director | 0 | — | — | $0 | 7 | 2008-04-03 |
Recent Filings · Page 2 of 9
88 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-14 | BNTC | Buy (P) | +51,813 | $0 | EDGAR |
| 2023-06-13 | Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Buy (P) | +21,858 | $6.3K | EDGAR |
| 2023-06-09 | Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Buy (P) | +25,000 | $7.4K | EDGAR |
| 2023-05-17 | Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Buy (P) | +32,534 | $8.9K | EDGAR |
| 2023-05-16 | Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Buy (P) | +67,466 | $16.4K | EDGAR |
| 2023-05-11 | AMRX | Mixed | +80,128 | $0 | EDGAR |
| 2022-12-09 | BNTC | Grant (A) | — | $0 | EDGAR |
| 2022-05-10 | AMRX | Mixed | +35,406 | $0 | EDGAR |
| 2022-01-03 | Ampio Pharmaceuticals, Inc. (AMPE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-29 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Mixed | −4,666 | -$178.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.